Kevin Núño

Mr. Kevin Núño

Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2024 in Molecular Aspects of Medicine
Verified
Journal Article
Closed access
KNKevin Núño
Kevin Núño
AJAnne Sophie Jensen
Anne Sophie Jensen
GOGregory O'COnnor
Gregory O'COnnor
THTiffani Janae Houston
Tiffani Janae Houston
EDEmre Dikici
Emre Dikici
Sylvia DaunertSylvia Daunert
Sylvia Daunert

28 December 2025 in npj Biofilms and Microbiomes
Verified
Journal Article
Open access
PDF file
MMMichael Moraskie
Michael Moraskie
SLSara Li
Sara Li
JCJosep-Ramon Codina
Josep-Ramon Codina
HRHarun Or Roshid
Harun Or Roshid
KNKevin Núño
Kevin Núño
Sylvia DaunertSylvia Daunert
Sylvia Daunert
The quorum-sensing molecule 3,5-dimethylpyrazine-2-ol (DPO), known for regulating biofilm formation in Vibrio cholerae, has unknown distribution among commensal bacteria. We screened 37 bacterial strains using a validated biosensor and found widespread production. Inoculating mice with high producers elevated gut DPO levels, highlighting DPO’s potential influence on gut microbiota. These findings expand DPO’s ecological relevance and underscore quorum sensing as a potentially critical influence on microbiome function and host-microbe interactions.

5 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SGSimonetta Ines Gaumond
Simonetta Ines Gaumond
IKIsabella Kamholtz
Isabella Kamholtz
LFLina M Ferrari
Lina M Ferrari
KNKevin Núño
Kevin Núño
MOMadisyn Opstal
Madisyn Opstal
JJJoaquín J. Jiménez
Joaquín J. Jiménez
Cannabidiol (CBD) is a non-intoxicating phytocannabinoid with increasingly recognized effects on cutaneous and hair follicle (HF) biology. This narrative review evaluates CBD-responsive signaling and its intersection with transcriptional, epigenetic, and post-transcriptional mechanisms relevant to HF cycling and alopecia, with particular emphasis on the hierarchy of experimental evidence. Available data indicate that CBD does not exert a uniformly pro-growth effect, but instead produces concentration-, compartment-, and context-dependent responses. In human HFs, submicromolar CBD primarily demonstrates anti-inflammatory activity, whereas micromolar exposure suppresses hair shaft production and promotes catagen through TRPV4-dependent Ca2+ signaling. CBD also modulates adenosine and Wnt/β-catenin pathways and can restore β-catenin expression in human dermal papilla cells under inhibitory conditions. Beyond acute receptor signaling, CBD influences DNA methylation, histone modifications, miRNA networks, and transcriptional regulators including PPARγ and AhR. However, most of this evidence derives from non-follicular systems, and direct CBD-induced epigenetic remodeling of human HFs has not been demonstrated. Among alopecia subtypes, AGA has the strongest mechanistic and preliminary clinical rationale, whereas evidence in AA and scarring alopecia remains largely indirect. Translation is further limited by uncertain intrafollicular CBD exposure, formulation-dependent delivery, and the absence of controlled clinical efficacy data. CBD should therefore be viewed as a context-dependent regulator of follicular signaling rather than an established hair growth treatment. Future studies should define follicular pharmacokinetics, establish concentration–response relationships, and test pathway causality in intact human HFs and disease-specific models.